Salomon Azoulay, Chief Medical Officer, on May 08, 2026, sold 70,003 shares in Mbx Biosciences (MBX) for $2,685,515. Following the Form 4 filing with the SEC, Azoulay has control over a total of 14,769 common shares of the company, with 14,769 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1776111/000119312526216704/xslF345X05/ownership.xml
Trent G Kamke, Senior Vice President, Operations, on May 08, 2026, sold 2,928 shares in Lemaitre Vascular (LMAT) for $313,287. Following the Form 4 filing with the SEC, Kamke has control over a total of 3,749 common shares of the company, with 3,749 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1158895/000119312526217113/xslF345X05/ownership.xml
Kurtis Joseph Binder, CFO, on May 08, 2026, sold 65,000 shares in Arlo Technologies (ARLO) for $1,020,474. Following the Form 4 filing with the SEC, Binder has control over a total of 499,885 common shares of the company, with 499,885 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1736946/000165473726000011/xslF345X05/form4-05112026_090526.xml
Lawrence J Jasinski, Director, on May 07, 2026, sold 3,943 shares in Lemaitre Vascular (LMAT) for $433,730. Following the Form 4 filing with the SEC, Jasinski has control over a total of 4,714 common shares of the company, with 4,714 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1158895/000119312526217096/xslF345X05/ownership.xml